Medicine Recommendations

Schizophrenia and other psychoses, mania, short term management of severe anxiety

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Drug induced extrapyramidal side effects

The colour classification was determined as part of the collaborative work between LCFT and Medicines Management leads. Local pathways and patient safety were taken into consideration.

Progestogenic opposition of oestrogen HRT in women with an intact uterus

Short-term management of psychomotor agitation, agitation and restlessness in the elderly

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Rapid tranquillisation

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Anxiety

Migraine prophylaxis

Treatment of chronic constipation in women (NICE TA211) and Use in men: Prucalopride for the treatment of chronic constipation in men (LSCMMG recommendation)

NICE TA211 - Prucalopride for the treatment of chronic constipation in women

Schizophrenia, manic episodes associated with bipolar disorder, major depressive episodes in bipolar disorder, preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment.

Schizophrenia, manic episodes associated with bipolar disorder, major depressive episodes in bipolar disorder, preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment, adjunct in major depressive disorder

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Primary prevention of osteoporotic fragility fractures in postmenopausal women (NICE TA160)

NICE TA160 - Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended) 

Secondary prevention of osteoporotic fragility fractures in postmenopausal women (NICE TA161)

NICE TA161  Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)

Age-related macular degeneration (NICE TA155)

NICE TA155 - Ranibizumab and pegaptanib for the treatment of age-related macular degeneration

Diabetic Macular Oedema (NICE TA274)

NICE TA274 - Ranibizumab for treating diabetic macular oedema (rapid review of technology appraisal guidance 237) 

Macular Oedema - retinal vein occlusion (NICE TA283)

NICE TA283 - Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion

Choroidal neovascularisation (pathological myopia) NICE TA298

NICE TA298 - Ranibizumab for treating choroidal neovascularisation associated with pathological myopia 

As adjunctive therapy in the treatment of stable angina in patients inadequately controlled or intolerant of first-line antianginal therapies

MS (unlicensed)

Parkinson's disease